Group One Trading
CATX icon

Group One Trading’s Perspective Therapeutics CATX Stock Holding History

Group One Trading’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02K Sell
300
-5,700
-95% -$21.5K ﹤0.01% 7176
2026
Q1 		$25K Buy
6,000
+1,000
+20% +$4.22K ﹤0.01% 5812
2025
Q4 		$13.8K Buy
+5,000
New +$14.3K ﹤0.01% 6617

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Group One Trading's CATX Position: Q2 2026 in Review

Group One Trading sold out of Perspective Therapeutics (CATX) in Q2 2026, closing a stake of 2,155 shares — an estimated $8.14K sold.

Group One Trading first reported a position in CATX in Q3 2024 and held it in 3 quarters. The position peaked at $10.4K in Q4 2025. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Group One Trading reported no remaining Perspective Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 2,155 Perspective Therapeutics shares in Q2 2026, an estimated $8.14K.
  • Group One Trading first reported a position in Perspective Therapeutics in Q3 2024 and held it in 3 quarters.
  • Group One Trading's Perspective Therapeutics position peaked at $10.4K in Q4 2025.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.